Neurocrine raises 2026 sales forecast for movement-disorder drug

Neurocrine Biosciences reported total revenue of $1.12 billion for the third quarter of 2026, representing a 41% increase year-over-year. The company's performance was driven by net product sales of $801 million for INGREZZA, $211 million for CRENESSITY, and $107 million for VYKAT XR. Adjusted earnings for the period were reported at $346.7 million, or $3.29 per share. Following these results, the company raised its 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion. CEO Kyle W. Gano highlighted the milestone of exceeding $1 billion in quarterly net product sales and noted the company's focus on upcoming clinical milestones, including Phase 3 readouts for osavampator and direclidine.